Vapreotide

DB04894InvestigationalProtein Based Therapies

Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.

Mechanism: The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407).
Curator reviewed
Primary indication: For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.Curator reviewed
Code names: BMY-41606 · RC-160

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of September 12, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

236Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 23 drug categories

25+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vapreotide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.